Condition: Refractory Metastatic Colorectal Cancer · Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants. The primary goal of Phase III Study is to evaluate the efficacy of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants. Researchers will compare Suvemcitug + trifluridine/tipiracil tablets with placebo (a look-alike substance that contains no drug)+ trifluridine/tipiracil tablets to see if Suvemcitug + trifluridine/tipiracil tablets works better in treating refractory metastatic colorectal cancer.
This description comes directly from the study's public registry record.
Xueyan Li · +86-25-85566666 · lixueyan1@zaiming.com
Always discuss trial participation with your own doctor first.
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| Harbin Medical University University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| The First Affiliated Hospital of Nanjing Medical University | Nanjing, Jiangsu, China | Recruiting |
| Cancer Hospital of Shandong First Medical University | Jinan, Shandong, China | Recruiting |
| Tianjin Medical University Cancer Institute and Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07361003